These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37913904)

  • 21. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
    Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
    Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early response to erythropoiesis-stimulating agents in non-dialysis chronic kidney disease patients.
    Kuwahara M; Arai Y; Takehara E; Sasaki Y; Yoshimine T; Kusaka K; Shikuma S; Akita W; Uchida S
    Clin Exp Nephrol; 2016 Aug; 20(4):585-594. PubMed ID: 26511877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilisation in Treatment of Anaemia in Patients with Chronic Kidney Disease.
    Hayashi T; Nagamatsu T; Matsushita A; Mizuno T; Nishibe S; Noguchi A; Kato R; Toda T; Tanaka J; Takahashi H; Hayashi H; Yuzawa Y; Yamada S
    Biol Pharm Bull; 2015; 38(5):740-5. PubMed ID: 25740003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
    Hörl WH
    Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach.
    Thavarajah S; Choi MJ
    Am J Kidney Dis; 2019 Nov; 74(5):667-674. PubMed ID: 31395400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years?
    Hung SC; Lin YP; Tarng DC
    J Formos Med Assoc; 2014 Jan; 113(1):3-10. PubMed ID: 24090633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
    J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease.
    Kim SM; Kim KM; Kwon SK; Kim HY
    J Korean Med Sci; 2016 Jan; 31(1):55-60. PubMed ID: 26770038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study.
    Tanaka S; Kitamura H; Tsuruya K; Kitazono T; Nakano T;
    Clin Exp Nephrol; 2022 Sep; 26(9):867-879. PubMed ID: 35507237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
    Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
    Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of anemia in children receiving chronic peritoneal dialysis.
    Borzych-Duzalka D; Bilginer Y; Ha IS; Bak M; Rees L; Cano F; Munarriz RL; Chua A; Pesle S; Emre S; Urzykowska A; Quiroz L; Ruscasso JD; White C; Pape L; Ramela V; Printza N; Vogel A; Kuzmanovska D; Simkova E; Müller-Wiefel DE; Sander A; Warady BA; Schaefer F;
    J Am Soc Nephrol; 2013 Mar; 24(4):665-76. PubMed ID: 23471197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?
    De Nicola L; Locatelli F; Conte G; Minutolo R
    Drugs; 2014 Feb; 74(2):159-68. PubMed ID: 24442793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of pharmacist-managed erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD.
    Aspinall SL; Cunningham FE; Zhao X; Boresi JS; Tonnu-Mihara IQ; Smith KJ; Stone RA; Good CB;
    Am J Kidney Dis; 2012 Sep; 60(3):371-9. PubMed ID: 22633556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
    Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
    Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of hemoglobin levels in individual hemodialysis patients by means of a mathematical model of erythropoiesis.
    Fuertinger DH; Kappel F; Zhang H; Thijssen S; Kotanko P
    PLoS One; 2018; 13(4):e0195918. PubMed ID: 29668766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. It's time to compare anemia management strategies in hemodialysis.
    Coyne DW
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Erythropoietin-Stimulating Agents (ESA) in Patients With End-Stage Renal Failure Decided to Forego Dialysis: Palliative Perspective.
    Cheng HW; Chan KY; Lau HT; Man CW; Cheng SC; Lam C
    Am J Hosp Palliat Care; 2017 May; 34(4):380-384. PubMed ID: 26718957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treating anaemia in patients with chronic kidney disease: what evidence for using ESAs, after a 30-year journey?].
    Locatelli F; Del Vecchio L; De Nicola L; Minutolo R
    G Ital Nefrol; 2020 Aug; 37(4):. PubMed ID: 32809282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.